Alzamend Neuro Files 8-K on Financials
Ticker: ALZN · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Alzamend Neuro dropped an 8-K on Dec 12th detailing financial results. Check it out.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on December 12, 2024, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides crucial updates on Alzamend Neuro's financial health and operational results, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Alzamend Neuro is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40483 (other) — Commission File Number
- 81-1822909 (other) — I.R.S. Employer Identification No.
- 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326 (address) — Address of principal executive offices
- (844) 722-6333 (phone_number) — Business Phone
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated December 12, 2024.
What is Alzamend Neuro, Inc.'s state of incorporation?
Alzamend Neuro, Inc. is incorporated in Delaware.
What is the principal executive office address for Alzamend Neuro, Inc.?
The principal executive office is located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
What is the Commission File Number for Alzamend Neuro, Inc.?
The Commission File Number is 001-40483.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-12-12 16:30:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
Filing Documents
- d12122438k.htm (8-K) — 28KB
- ex99_1.htm (EX-99.1) — 14KB
- alzamendlogo_regmark.jpg (GRAPHIC) — 17KB
- 0001214659-24-020439.txt ( ) — 246KB
- alzn-20241212.xsd (EX-101.SCH) — 3KB
- alzn-20241212_lab.xml (EX-101.LAB) — 33KB
- alzn-20241212_pre.xml (EX-101.PRE) — 24KB
- d12122438k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On December 12, 2024, Alzamend Neuro, Inc. (the " Company ") issued a press release announcing its unaudited financial results for the six months ended October 31, 2024 (the " Press Release "). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are "forward-looking reflect the Registrant's judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as "expects," "should," "will," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on For
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated December 12, 2024 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: December 12, 2024 /s/ David J. Katzoff David J. Katzoff Chief Financial Officer 3